AGIO Agios Pharmaceuticals Inc.

77.70
-1.09  -1%
Previous Close 78.79
Open 78.21
Price To book 11.86
Market Cap 4454287776
Shares 57,326,741
Volume 294,314
Short Ratio 6.24
Av. Daily Volume 661,222

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 updated data due at ASCO 2018.
Enasidenib or ivosidenib with VIDAZA
Frontline AML with IDH1 or IDH2 mutation
Phase 1 first data presented at ASH 2017 with updated data due at ASH 2018. Phase 3 trial to be initiated 4Q 2018.
Ivosidenib or enasidenib
Frontline AML with IDH1 or IDH2 mutation
First data due from expansion trial at ASH December 11, 2017. Updated data due at ASCO 2018.
Ivosidenib
R/R Acute Myeloid Leukemia (AML)
Phase 2 trial to be initiated 4Q 2018.
AG-348
Thalassemia
PDUFA date under priority review August 21, 2018.
Ivosidenib
IDH1m Relapsed/Refractory AML - cancer
Pivotal trials to be initiated 1H 2018.
AG-348
Pyruvate kinase deficiency
Phase 3 initiated 2Q 2017.
AG-120 and VIDAZA - AGILE
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
Phase 3 initiated December 2016.
AG-120
IDH1 mutant positive cholangiocarcinoma - cancer

Latest News

  1. FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
  2. FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation
  3. Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y
  4. Agios Pharmaceuticals reports 4Q loss
  5. Agios Reports Fourth Quarter and Full Year 2017 Financial Results
  6. Agios Pharmaceuticals, Inc. to Host Earnings Call
  7. Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
  8. Why Agios Pharmaceuticals Shares Jumped 37.8% in January
  9. Agios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018
  10. Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
  11. Celgene's Investments Are Soaring
  12. Agios sizes up funding needs
  13. Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year
  14. Agios Announces Pricing of $475 Million Public Offering of Common Stock
  15. Agios Announces Proposed Offering of Common Stock
  16. See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
  17. Today’s Research Reports on Stocks to Watch: Agios Pharmaceuticals, Inc. and Ironwood Pharmaceuticals, Inc.
  18. Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 81 RS Rating
  19. How Did Bioverativ Perform in 3Q17?
  20. Analysts’ Recommendations for Bioverativ in January 2018